

24 April 2024

Study title: A Phase 2 Placebo-controlled Double Blinded Study to Assess the Efficacy and Safety of Belimumab in Subjects with Immunoglobulin A Nephropathy (IgAN)
EudraCT Number: 2017-004366-10
Protocol number: 0642

The above study was terminated early on 11th May 2023 following funder confirmation that they were no longer in a position to support the trial.

There were no issues or concerns regarding the design of the trial or participant safety relating to this decision. No participants were recruited and the trial is now closed.

Yours sincerely



Kyla Harrington
Clinical Trials Governance Manager
University of Leicester

e: kyla.harrington@le.ac.uk & rgosponsor@le.ac.uk